ClinicalTrials.gg
CompletedNCT01671787Updated Oct 23, 2018

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

A Phase 1 interventional study of GS-7340 and Tenofovir disoproxil fumarate in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 19 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.

Enrollment
19th of 26
51 · median 124
Started
2012
the only one that year
Phase 1
4 of 26
none open now
Registered
1st of 26
by date
Lead sponsor
5 of 26
Gilead Sciences

Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 19th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 1, and was the 1st registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This is an open-label study evaluating multiple doses of GS-7340 versus Tenofovir disoproxil fumarate (TDF).

Read the detailed description

This is a randomized, open-label, active-controlled study whose primary objective is to evaluate the safety and efficacy of several doses of GS-7340. This study will evaluate the safety, viral kinetics, and antiviral activity of 4 different doses of GS-7340 over 28 days of therapy. In addition, the study will evaluate the antiviral activity of an optimal dose of GS-7340 versus 300mg Tenofovir disoproxil fumarate (TDF) over 28 days of therapy.

03

Conditions studied

  • Chronic Hepatitis B

Keywords

  • Hepatitis B
  • HBV
  • GS-7340
  • TDF
  • Tenofovir disoproxil fumarate
  • Gilead
  • Viread
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be between 18 and 65 years of age
  • Must have Screening plasma ≥ 2x10\^3 IU/mL
  • Must have chronic HBV infection for at least 6 months
  • Must have estimated (CLCr) ≥ 70 mL/min
  • Not pregnant or nursing
  • Women must be of non- OR of childbearing potential with confirmed negative pregnancy tests
  • Consistent and correct use of recommended methods of for men and women

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating subjects
  • Receipt of anti- nucleoside/nucleotide therapy. Subjects who have failed prior Interferon treatment, greater than 6 months prior to screening, are permitted to participate in the study screening
  • Known co-infection with , virus (HCV) or hepatitis D virus (HDV)
  • Presence of disorders
  • History of liver disease other than Hepatitis B
  • History of Gilbert's Disease
  • Any sign of decompensated liver disease
  • Known or suspected cirrhosis
  • Evidence of hepatocellular carcinoma
  • Presence or history of cardiovascular disease, cardiomyopathy, and/or cardiac conduction abnormalities
  • Electrolyte abnormalities
  • History of treatment that permanently alters the gastric condition
  • Alcohol or substance abuse
  • History of bleeding diathesis
  • Significant bone disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    GS-7340 8mg

    After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.

    Drug: GS-7340

  • Experimental
    GS-7340 25mg

    After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.

    Drug: GS-7340

  • Experimental
    GS-7340 40mg

    After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.

    Drug: GS-7340

  • Experimental
    GS-7340 120mg

    After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.

    Drug: GS-7340

  • Experimental
    Tenofovir disoproxil fumarate 300mg

    After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.

    Drug: Tenofovir disoproxil fumarate

Interventions

  • Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.

  • Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy

    Also known as: Viread

06

What researchers measure

Primary outcomes

  1. Change in serum hepatitis B virus (HBV) DNA

    Time-weighted average change from baseline through Week 4 (DAVG4) in serum HBV DNA (log10 IU/mL) for GS-7340 8-, 25-, 40 and 120-mg.

    Time frame: Up to Week 4

Secondary outcomes

  1. Change in HBV DNA for tenofovir disoproxil fumarate (TDF)

    Comparing the short-term antiviral activity of GS-7340 with TDF 300mg. This is measured by time-weighted average change from baseline through Week 4 (DAVG4) in serum HBV DNA (log10 IU/mL) for TDF.

    Time frame: Up to Week 4

  2. Change in HBV DNA of GS-7340 through 28 days of therapy

    Time weighted change from baseline to day 29 (DAVG4) in serum HBV DNA (log10 IU/mL)

    Time frame: Up to week 4

  3. Pharmacokinetics (PK) of GS-7340 and/or tenofovir (TVF) following single and multiple doses of GS-7340 and TDF

    GS-7340 and tenofovir (TFV) PK parameters in plasma will be calculated as applicable: Cmax, Tmax, Clast, Tlast, T1/2, λz, AUC0-t, AUC0-last, AUC0-∞, %AUCexp. PK samples are collected on: * Baseline/Day 1: 0 (predose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose * Additional predose plasma samples will be collected on Days 2, 5, 8, 10, 15, 19, 22, and 29/End of Treatment.

    Time frame: Up to week 4

  4. Safety and Tolerability of Therapy

    Safety and tolerability is measured by the incidence of adverse events and graded laboratory abnormalities

    Time frame: Up to week 4

07

Study locations

19 sites
  • Research and Education Inc.
    San Diego, California 92105, United States
  • University of Maryland Institute of Human Virology
    Baltimore, Maryland 21201, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Baylor College of Medicine - St. Luke's Episcopal Hospital
    Houston, Texas 77030, United States
  • Monash Medical Centre
    Melborne, Victoria 03168, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Austin Health
    Melbourne, Victoria 3084, Australia
  • Linear Clinical Research Ltd
    Nedlands, Western Australia 6009, Australia
  • Downtown Infectious Diseases Clinic (University of British Columbia)
    Vancouver, British Columbia V6Z2C9, Canada
  • The Ottawa Hospital, General Campus
    Ottawa, Ontario K1H8L6, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Algorithme Pharma
    Montreal, Quebec H3P3P1, Canada
  • Pro-recherche
    St. Romuald, Quebec G6W 8H1, Canada
  • Auckland Clinical Studies
    Auckland, 1042, New Zealand
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B152TH, United Kingdom
  • Grahame Hayton Unit
    London, E1 1BB, United Kingdom
  • University College London Hospital
    London, NW1-2BU, United Kingdom
  • Institute of Liver Studies, King's College Hospital
    London, SE5 9RS, United Kingdom
  • Nottingham University Hospitals NHS Trust - Queens Medical Centre
    Nottingham, NG7 2UH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2012
First posted
Aug 24, 2012
Start
Mar 2012
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01671787
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 24, 2012
Start date
Mar 2012
Primary completion
Apr 2013
Completion
Apr 2013
Last update
Oct 23, 2018

Study contacts

John Flaherty, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tenofovir alafenamide · Tenofovir

Start the discussion